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Abstract: BACKGROUND: The incidence of melanoma has been steadily rising in past decades. Although it accounts
for only 3% of all skin cancers, it is responsible for 75% of deaths. OBJECTIVE: to describe the epidemiological
aspects of melanoma in a university hospital setting over a period of 20 years. METHODS: A total of 166 patients
were analyzed between January 1990 and January 2010 for clinical and histological variables and correlations
between them. A 5% level of significance was adopted. RESULTS: The majority of patients were Caucasians (74%),
females (61%), with a mean age at diagnosis of 55. The predominant histological type was lentigo maligna/lenti-
go maligna melanoma (35.7%) and the head and neck was the most affected site (30.7%). Among non-Caucasians,
the acral region was the most affected. Most tumors were in situ (41.1%). Growth of the lesion was the most fre-
quent complaint (58.1%) and bleeding was most frequently associated with melanomas with a depth > 4mm.
There were seven deaths (4.2%), with a high risk among men, non-Caucasians and those under 20 years of age,
with a Breslow’s depth > 2mm, with lentiginous acral melanoma and with a history of growth and bleeding.
CONCLUSIONS: Our sample differs from most of the studies in the predominant location (head and neck), histolog-
ical type (lentigo maligna/ lentigo maligna melanoma) and a major risk of death under the age of 20, which could
be with a reflex of regional variation. Broader studies are necessary for validation of the results.
Keywords: Epidemiology; Lentigo; Melanoma
Resumo: FUNDAMENTOS: A incidência do melanoma cutâneo aumentou nas últimas décadas. Embora represente
3% dos tumores cutâneos, é responsável por 75% dos óbitos. O diagnóstico precoce constitui a principal chance de
cura. OBJETIVO: Descrever os aspectos epidemiológicos do melanoma em hospital universitário em 20 anos.
MÉTODOS: Avaliaram-se 166 pacientes no período de janeiro de 1990 a janeiro de 2010, quanto às variáveis epide-
miológicas, histológicas e óbitos relacionados ao melanoma e suas correlações. Adotou-se nível de significância de
5%. RESULTADOS: A maioria dos pacientes era brancos (74%), mulheres (61%), com média de idade ao diagnóstico
de 55 anos. O tipo histológico predominante foi o lentigo maligno/lentigo maligno melanoma (35,7%) e a locali-
zação mais frequente foi a cabeça e o pescoço (30,7%). Entre os não-brancos, a região acral foi a mais acometida.
Quanto à espessura tumoral, a maioria dos melanomas era in situ (41,1%). O crescimento da lesão foi a queixa mais
frequente (58%) e o sangramento foi mais associado a melanomas espessos. Ocorreram sete óbitos (4,2%), com
maior risco de morte em menores de 20 anos e naqueles com história de sangramento, após análise multivariada.
CONCLUSÃO: Esta casuística difere da maioria dos estudos em relação à localização (cabeça e pescoço), ao tipo his-
tológico (lentigo maligno/lentigo maligno melanoma) e ao maior risco de óbito em menores de 20 anos, o que
pode ser devido à variação regional. Estudos mais amplos são necessários para validação destes resultados.
Palavras-chave: Epidemiologia; Lentigo; Melanoma
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INTRODUCTION
The incidence of cutaneous melanoma (CM)
has increased continuously in recent decades around
the world.1 The highest rates, 40 to 60 cases per
100,000 inhabitants, are found in Australia and New
Zealand.2,3 In the USA, the incidence of CM rose from
8.7 to 26.5 per 100,000 inhabitants from 1975 to 2007,
an increase of 300%.4 In Brazil, the estimated incidence
of CM for 2010, according to the National Cancer
Institute (INCA) varies from 3.04 to 3.72 per 100,000
men and 2.92 to 3.04 per 100,000 women, with the
highest rates in the Southern region of the country.5
In recent years, survival rates have improved,
probably due to earlier diagnosis.3,5 Two thirds of all
cases of CM diagnosed in the USA between 1988 and
1999 had a tumor thickness of < 1 mm, while the pro-
portion of CM ≥ 2 mm remained stable.6
Various environmental and constitutional risk
factors are found to be associated with CM. Among
the former, intermittent exposure to sunlight, especial-
ly that which results in burns accompanied by blisters
during childhood, has been referred to as the most rel-
evant.7,8 As for constitutional risk factors, of note are
lighter phototypes (types I and II on the Fitzpatrick
scale), congenital nevus, multiple acquired common
or atypical melanocytic nevi, a personal and/or fami-
ly history of CM, xeroderma pigmentosum, a person-
al history of other skin cancers and immunosuppres-
sion.9,10
The more refined knowledge of the epidemio-
logical and histological characteristics of CM may be
reflected in the approach taken towards it, especially
favoring early diagnosis.
MATERIAL AND METHODS
One hundred and sixty-six patients from the
dermatology center at a university hospital were diag-
nosed with CM from January of 1990 to January of
2010. The sample was defined for convenience.
The following clinical variables were analyzed:
sex, age at diagnosis (< 20, 21-40, 41- 60 and > 60), skin
color (white and non-white), body location (head and
neck, trunk, upper limbs, lower limbs, acral regions
and others), atypical nevi (none, < 10 and > 10), non-
melanoma skin cancer, non-cutaneous cancer, family
history of CM, symptoms and/or signs (bleeding,
itching, pain and burning sensation, changes in color
or size), metastasis and deaths. 
The histological variables analyzed were: histo-
logical type (superficial spreading melanoma [SSM],
nodular melanoma [NM], acral-lentiginous
melanoma [ALM], lentigo maligna / lentigo maligna
melanoma [LM/LMM] and others), tumor thickness
(in situ ≤1 mm, 1.01-2 mm, 2.01–4 mm and >4 mm)
and the level of invasion or Clark level (in situ or I, II,
III, IV and V).
A significance level of 5% was considered. The
variables were compared based on the Chi-squared
test and Fisher Exact test. 
The progression towards death was evaluated
based on survival analysis techniques. Only deaths
resulting from CM were considered. A univariate
analysis was performed utilizing the log-rank test and
the multivariate analysis was conducted using the
Cox model.
This study was approved by the Research
Ethics Committee, and terms of free and informed
consent were duly collected.
RESULTS
In the sample assessed, 101 patients (61%) were
women and 65 (39%) were men. The mean age at
diagnosis was 55, with standard deviation of 18,2
years. The minimum age was one year and the maxi-
mum 92 years (Graph 1). The sample consisted of 120
whites (74%) and 42 non-whites (26%).
Regarding body location, 30.7% of the patients
presented CM on the head and neck, 21.1% on the
trunk, 19.3% in acral regions, 15.1% in the upper limbs
and 9.6% on the lower limbs. In a comparison
between genders, the men presented a higher propor-
tion of MM on the head and neck (35.3%), followed by
the trunk (29.2%). Among the female patients, the
extremities (upper and lower limbs) were the most
frequent site (34.7%), followed by the head and neck
(27.7%). The women presented more affected areas on
the lower limbs (13.9%) than the men (3.1%), while
among men CM affected the trunk more (29.2%) than
among women (15.8%). The white patients had a
greater proportion of CM on the head and neck
(35.9%), followed by the trunk (25.8%). Among non-
GRAPH 1:  Histogram of age at diagnosis
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TABLE 1: Comparison between location and sex, skin color, age at diagnosis, histological type and signs and symptoms
Characteristics Head and Acral Trunk Upper limb Lower limb Others p-value 
neck
Sex
Male 23 35.3 13 20.0 19 29.2 4 6.2 2 3.1 4 6.2 0.0061
Female 28 27.7 19 18.8 16 15.8 21 20.8 14 13.9 3 3.0
Skin color
White 43 35.9 10 8.3 31 25.8 21 17.5 12 10.0 3 2.5 <0.0011
Non-white 7 16.7 21 50.0 4 9.5 4 9.5 4 9.5 2 4.8
Age at diagnosis 
1)<20 1 14.2 1 14.3 2 28.6 2 28.6 0 0.0 1 14.3 ...
21-40 8 28.5 5 17.9 7 25.0 4 14.3 1 3.6 3 10.7
41-60 19 30.1 10 15.9 15 23.8 9 14.3 8 12.7 2 3.2
>60 23 33.8 16 23.5 11 16.2 10 14.7 7 10.3 1 1.5
2) ≤40 9 25.7 6 17.1 9 25.7 6 17.1 1 2.9 4 11.5 0.1511
>40 42 32.1 26 19.8 26 19.8 19 14.5 15 11.5 3 2.3
3) ≤60 28 28.6 16 16.3 24 24.5 15 15.3 9 9.2 6 6.1 0.4531
>60 23 33.8 16 23.5 11 16.2 10 14.7 7 10.3 1 1.5
Histological type
1) LM/LMM 29 53.7 3 5.6 8 14.8 10 18.5 4 7.4 0 0.0 ...
SSM 14 26.4 0 0.0 18 34.0 12 22.6 8 15.1 1 1.9
NM 3 33.4 0 0.0 2 22.2 2 22.0 2 22.2 0 0.0
ALM 0 0.0 23 88.5 2 7.7 0 0.0 1 3.8 0 0.0
Others 1 11.1 2 22.2 1 11.1 0 0.0 0 0.0 5 56.6
2) LM/LMM 29 53.7 3 5.6 8 14.8 10 18.5 4 7.4 0 0.0 <0.0011
Others 18 18.6 25 25.8 23 23.7 14 14.4 11 11.3 6 6.2
Signs and symptoms
Yes 31 32.3 21 21.8 16 16.7 14 14.6 11 11.5 3 3.1 0.1441
No 13 32.5 3 7.5 14 35.0 6 15.0 3 7.5 1 2.5
Bleeding
Yes 1 14.3 3 42.8 1 14.3 1 14.3 0 0.0 1 14.3 0.1641
No 43 33.3 21 16.3 29 22.5 19 14.7 14 10.9 3 2.3
Alterations in sensitivity
Yes 5 25.0 4 20.0 5 25.0 3 15.0 2 10.0 1 5.0 0.9081
No 39 33.6 20 17.2 25 21.6 17 14.7 12 10.3 3 2.6
Darkening
Yes 10 33.3 4 13.3 5 16.7 7 23.4 4 13.3 0 0.0 0.5691
No 34 32.0 20 18.9 25 23.6 13 12.3 10 9.4 4 3.8
Growth
Yes 29 36.7 19 24.0 10 12.7 10 12.7 9 11.4 2 2.5 0.0131
No 15 26.3 5 8.8 20 35.1 10 17.5 5 8.8 2 3.5
1: Fisher Exact test,   .... No test
N % N % N % N % N % N %
Location
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whites, acral regions corresponded to 50% of the cases
(Table 1).
Among histological types, LM/LMM was
found in 35.7% of the cases, followed by SSM in 35.1%,
ALM in 17.2% and NM in 6%. In a comparison respec-
tive to body locations, LM/LMM was the most fre-
quent histological type on the head and neck. ALM
was present in 88.5% of the CM cases located in acral
regions, while SSM was most common on the trunk
(34%).
Correlated with skin color, the white patients
presented a predominance of SSM (43.5%), followed
by LM/LMM (35.2%). Among the non-whites, 40%
presented with ALM, followed by LM/LMM (37.5%)
(Table 2 and Graph 2).
Roughly 20% of the patients had atypical nevi,
with 16.5% presenting less than 10 and 3.4% more
than 10 such lesions.
A family history of CM was present in 16 (10%)
of the patients.
Regarding tumor thickness, 41.1% were in situ,
31.1% presented a tumor thickness < 1 mm, 11.3%
were between 1.01 and 2 mm and 9.9% were between
2.01 and 4mm, 6.6% were > 4 mm. In a comparison of
histological types, LM/LMM was the most frequent
among in situ CM or CM with a tumor thickness ≤ 1
mm (92.3%), followed by SSM (73.1%). There was no
statistically significant difference in the correlations
between tumor thickness and gender, skin color, age
and body location (Table 3).
In relation to the Clark level, 42% of the patients
1: Fisher Exact test,   .... No test
TABLE 2: Comparison between histological type and skin color and age at diagnosis
Characteristics LM /LMM SSM NM ALM Others p-value
Skin color
White 38 35.2 47 43.5 9 8.3 10 9.3 4 3.7 <0.0011
Non-whites 15 37.5 6 15.0 0 0.0 16 40.0 3 7.5
Age at diagnosis 
1) <20 2 33.3 2 33.3 0 0.0 1 16.7 1 16.7 ...
21- 40 5 19.2 11 42.3 2 7.7 5 19.2 3 11.5
41 -60 19 33.9 20 35.7 5 8.9 8 14.3 4 7.1
>60 28 44.4 20 31.8 2 3.2 12 19.1 1 1.6
2) ≤40 7 21.9 13 40.6 2 6.3 6 18.8 4 12.5 0.2031
>40 47 39.5 40 33.6 7 5.9 20 16.8 5 4.2
3) ≤60 26 29.5 33 37.5 7 8.0 14 15.9 8 9.1 0.1071
>60 28 44.4 20 31.7 2 3.2 12 19.0 1 1.6
N % N % N % N % N %
Histological type
GRAPH 2: Distribution of histological type by skin color
presented at level 1 or in situ, 13% at level II, 20% at
level III, 21% at level IV and 4% at level V. The
LM/LMM histological type was the most common at
Clark levels I and II (84%). Among cases of level V
CM, ALM was the most common histological type
(11.5%) (Table 4).
Symptoms of and/or alterations in the primary
lesion were reported by 96 (70.6%) of the patients.
Among these, the most frequent report was of growth
of the lesion (58.1%), followed by alterations in color
by 22%, alterations in sensitivity by 14.7% and bleed-
ing by 5.2%. Darkening was the most common alter-
ation in color, while itching was the most common
symptom regarding sensitivity. Reports of bleeding
were most common for Clark levels IV and V (83.3%),
along with tumor thicknesses > 4 mm (60%). Growth
was most commonly reported for level I tumor inva-
sions (50%). Alterations in sensitivity and color were
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TABLE 3: Comparison between tumor thickness and sex, skin color, age at 
diagnosis, histological type and signs and symptoms
Characteristics In situ <1.0 1.01-2,0 2.01- 4.0 >4.0 p-value
Sex
Male 20 35.7 18 32.1 10 17.9 5 8.9 3 5.4 0.3751
Female 42 44.2 29 30.5 7 7.4 10 10.5 7 7.4
Skin color
White 40 36.1 39 35.1 14 12.6 10 9.0 8 7.2 0.2931
Non-white 21 55.3 8 21.1 3 7.8 4 10.5 2 5.3
Age at diagnosis
1) <20 4 66.6 1 16.7 0 0.0 0 0.0 1 16.7 ...
21 - 40 11 42.3 9 34.6 2 7.7 4 15.4 0 0.0
41 - 60 19 34.5 21 38.2 8 14.5 4 7.3 3 5.5
>60 28 43.8 16 25.0 7 10.9 7 10.9 6 9.4
2) ≤40 15 46.9 10 31.2 2 6.3 4 12.5 1 3.1 0.7521
>40 47 39.5 37 31.1 15 12.6 11 9.2 9 7.6
3) ≤60 34 39.1 31 35.6 10 11.5 8 9.2 4 4.6 0.5631
Histological type
1) SSM 12 23.1 26 50.0 9 17.3 4 7.7 1 1.9 ...
LM/LMM 35 67.3 13 25.0 1 1.9 3 5.8 0 0.0
NM 0 0.0 1 14.3 1 14.3 3 42.8 2 28.6
ALM 13 52.0 4 16.0 3 12.0 3 12.0 2 8.0
2) LM/LMM 35 67.3 13 25.0 1 1.9 3 5.8 0 0.0 <0.0011
Others 25 29.1 31 36.0 14 16.3 10 11.6 6 7.0
Location
1) Head and neck    24 52.2 11 23.9 5 10.9 5 10.9 1 2.2 ...
Acral 13 44.8 5 17.3 3 10.3 3 10.3 5 17.3
Trunk 12 36.3 11 33.3 5 15.2 3 9.1 2 6.1
Upper limb 9 36.0 12 48.0 1 4.0 2 8.0 1 4.0
Lower limb 4 26.7 7 46.6 3 20.0 1 6.7 0 0.0
Others 0 0.0 1 33.3 0 0.0 1 33.3 1 33.3
2) Head and neck 24 52.2 11 23.9 5 10.9 5 10.9 1 2.2 0.2931
Others 38 36.2 36 34.3 12 11.4 10 9.5 9 8.6
Signs and symptoms
Yes 37 41.1 27 30.0 10 11.1 10 11.1 6 6.7 0.2871
No 15 40.5 17 46.0 3 8.1 2 5.4 0 0.0
Bleeding
Yes 0 0.0 1 20.0 0 0.0 1 20.0 3 60.0 <0.0011
No 52 42.6 43 35.2 13 10.7 11 9.0 3 2.5
Alterations in sensitivity
Yes 5 27.8 6 33.3 3 16.7 4 22.2 0 0.0 0.1831
No 47 43.1 38 34.9 10 9.2 8 7.3 6 5.5
Darkening
Yes 10 33.3 9 30.0 5 16.7 3 10.0 3 10.0 0.2841
No 42 43.3 35 36.1 8 8.2 9 9.3 3 3.1
Growth
Yes 36 48.6 22 29.7 5 6.8 6 8.1 5 6.8 0.0991
No 16 30.2 22 41.5 8 15.1 6 11.3 1 1.9
1: Fisher Exact test,   .... No test
N % N % N % N % N %
Tumor thickness (mm)
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1: Fisher Exact test,   .... No test
TABLE 4: Comparison between Clark’s level and sex, skin color, age at diagnosis, 
histological type, signs and symptoms and location
Characteristics I II III IV V p-value
Sex
Male 20 37.0 8 14.8 12 22.2 11 20.4 3 5.6 0.7541
Female 42 45.2 11 11.8 16 17.2 21 22.6 3 3.2
Skin color
White 41 38.0 14 13.0 25 23.1 25 23.1 3 2.8 0.0971
Non-white 21 53.8 5 12.8 3 7.7 7 18.0 3 7.7
Age at diagnosis
1) <20 4 80.0 1 20.0 0 0.0 0 0.0 0 0.0 ...
21 - 40 11 44.0 1 4.0 8 32.0 5 20.0 0 0.0
41 -60 19 34.6 11 20.0 11 20.0 13 23.6 1 1.8
>60 28 45.1 6 9.7 9 14.5 14 22.6 5 8.1
2) ≤40 15 50.0 2 6.6 8 26.7 5 16.7 0 0.0 0.3841
>40 47 40.2 17 14.5 20 17.1 27 23.1 6 5.1
3) ≤60 34 40.0 13 15.3 19 22.3 18 21.2 1 1.2 0.1861
Histological type
1) SSM 13 26.0 6 12.0 18 36.0 13 26.0 0 0.0 ...
LM/LMM 34 68.0 8 16.0 5 10.0 1 2.0 2 4.0
NM 0 0.0 0 0.0 1 12.5 7 87.5 0 0.0
ALM 13 50.0 3 11.5 2 7.8 5 19.2 3 11.5
2) LM/LMM 34 68.0 8 16.0 5 10.0 1 2.0 2 4.0 <0.0011
Others 26 30.6 9 10.6 22 25.9 25 29.4 3 3.5
Signs and symptoms 
Yes 37 42.5 11 12.6 17 19.6 17 19.6 5 5.7 0.5301
No 15 41.6 6 16.7 10 27.8 5 13.9 0 0.0
Bleeding
Yes 0 0.0 0 0.0 1 16.7 3 50.0 2 33.3 0.0021
No 52 44.5 17 14.5 26 22.2 19 16.2 3 2.6
Alterations in sensitivity
Yes 5 29.4 3 17.7 3 17.7 6 35.2 0 0.0 0.3091
No 47 44.4 14 13.2 24 22.6 16 15.1 5 4.7
Darkening
Yes 10 33.3 5 16.7 7 23.3 6 20.0 2 6.7 0.7031
No 42 45.2 12 12.9 20 21.5 16 17.2 3 3.2
Growth
Yes 36 50.0 9 12.5 12 16.7 10 13.9 5 6.9 0.0391
No 16 31.4 8 15.7 15 29.4 12 23.5 0 0.0
Location
1) Head and neck 23 50.0 7 15.2 5 10.9 9 19.5 2 4.4 ...
Acral 13 43.4 4 13.3 1 3.3 8 26.7 4 13.3
Trunk 13 43.3 2 6.7 7 23.3 8 26.7 0 0.0
Upper limb 9 36.0 5 20.0 7 28.0 4 16.0 0 0.0
Lower limb 4 26.7 1 6.6 7 46.7 3 20.0 0 0.0
Others 0 0.0 0 0.0 1 100.0 0 0.0 0 0.0
2) Head and neck 23 50.0 7 15.2 5 10.9 9 19.5 2 4.4 0.4241
Others 39 38.6 12 11.9 23 22.8 23 22.8 4 3.9
N % N % N % N % N %
Clark’s level
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associated with in situ and thin CM (Breslow’s depth
≤ 1 mm), with 61.1% and 63.3% of cases, respectively,
but for the last two characteristics there was no statis-
tical significance (Tables 3 and 4).
Metastasis was detected in 19 (13.4%) patients.
Lymph node metastasis was found in 12 (40%)
patients, cutaneous in seven (24%), cerebral in five
(17%), lung in four (13%), blood in one (3%) and bone,
also in one patient (3%).
There were seven deaths resulting from CM.
We have included here patients with giant congenital
melanocytic nevi (GCMN) and xeroderma pigmento-
sum (PX). In the univariate analysis, there was a
greater chance of death for men, those under the age
of 20, non-whites, those with a Breslow’s depth > 2
mm, with the ALM histological type and with a histo-
ry of growth and bleeding. However, following the
multivariate analysis, only those under the age of 20
and those with a history of bleeding continued to run
a high relative risk of death, approximately 13 and
eight times higher, respectively (Table 5).
DISCUSSION
In countries with a lower incidence of CM, such
as European countries and Brazil, the majority of cases
occur among females and, in contrast, in countries
with the high incidence, such as Australia, New
Zealand and the USA, there is a predominance of the
disease among males or even equality in terms of gen-
der distribution.2
In this study, 61% of the patients were female,
which is in line with the majority of studies that have
been conducted in Brazil.11-16
In relation to age, CM is characterized by its
incidence among young people. The average age at
diagnosis is 52, which is 10 years less than what is
reported for more common cancers such as breast,
lung and prostate cancer.17 In this study, a mean age of
55 years was found, which is in consonance with
Brazilian and international literature.11,13, 14, 18-20
Among risk factors for CM are phenotypical
traits such as light or fair skin, hair and eyes, with
studies indicating a risk of developing this neoplasm
10 times higher among Caucasians than other ethnici-
ties.9,10 In the Southern region of Brazil, the majority of
studies deal with a population that is almost 100%
white.12,15 In this study, 74% of the patients were white
and 26% were non-whites. This ratio of non-whites is
higher than that found in the literature studied.11,16,21,22
Regarding histological type, the international
literature reports that among white individuals, SSM
predominates, varying from 37.7% in Chile to 43.6% in
Argentina, 60% in Spain, 62% in Switzerland and
73.6% in Australia.19,23-26 In studies involving non-white
individuals, ALM is the most prevalent.10,27 Forman et
al, in the USA, however, found that 56% of the cases
were LM/LMM and speculated whether this differ-
ence in relation to other studies is due to a change in
risk factors or to a regional peculiarity.28
In the Brazilian literature, in the Southern
region, where there is a prevalence of people with a
light skin tone, SSM vary from 35.3 to 68.9%.12,14,29-35 In
other regions in Brazil, where there is a greater pro-
portion of non-whites, the SSM percentage is lower.16,22
Fernandes et al found a predominance of LM/LMM
(29.8%), as did the present study.21 Despite the fact that
the difference in proportion between LM/LMM
(35.7%) and SSM (35.1%) found in this sample was
small, the frequency of LM/LMM is still higher than
that reported in the literature (5 to 10%), just as SSM is
less frequent when compared with studies in which a
white population is predominant (70%).10 This differ-
ence may be due to the frequency of non-whites found
in this study (26%) and possibly to sun exposure pat-
terns, although this last variable has not been meas-
ured.
In the current sample, SSM was most frequent
on the trunk and on the extremities and ALM was
responsible for almost 90% of the MM in acral regions.
LM/LMM was the most common histological type on
the head and neck, which is in concordance with the lit-
erature.1 A higher proportion of ALM was found
(17.2%) and, once again, the most plausible explanation
is the elevated frequency of non-whites in this sample.
TABLE 5: Multivariate model  - evolution to death
Age at diagnosis
<20 2.6 1.3 0.043 13.1 1.1 a 156.5
21 - 40 0.6 1.4 0.690 1.8 0.1 a 28.7
41 - 60 -0.4 1.4 0.790 0.7 0.04 a 11.1
>60 1.0
Bleeding
Yes 2.1 1.0 0.029 8.3 1.2 a 54.9
No 1.0
Final model Coefficient Standard error p-value Relative risk Confidence interval 95%
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The most common body location varies with
gender and with the histological type. In the majority
of studies, CM occurs with greater frequency on
men’s dorsal area and on women’s legs.10
In Brazilian literature, two studies11,33 found a
predominance of CM on the head and neck, as was
found in the present study.
The risk of CM is increased in the presence of
atypical melanocytic nevi.10 Gandini and collabora-
tors, in a meta-analysis study, highlighted that finding
an atypical nevus increased the risk of CM by 2.4
times, while 10 or more atypical nevi increased the
risk by 32 times.36 In the present study, approximately
20% of the patients presented atypical nevi, which is a
rate similar to that described in the literature.12,37
The risk of CM is higher in patients that suffer
from non-melanoma skin cancer, including basal-cell
carcinoma (BCC) and squamous-cell carcinoma
(SqCC), since all three neoplasms are related to sun
exposure.38 In the present study, the finding of 27,7%
of the patients with a history of non-melanoma skin
cancer is higher than that found in the literature.39,40
One possible explanation would be the chronic expo-
sure to the sun, which may also explain the elevated
frequency of CM on the head and neck, even though
this feature has not been evaluated by this study.
A family history of CM is an important risk fac-
tor. Patients with a history of CM8 among their rela-
tives face a risk twice as high, while three or more fam-
ily members with CM may result in a risk that is 35 to
70 times higher.10 A history of CM in the family was
observed in 10% of the cases, which is similar to the
rate described by the majority of the authors.1, 8-10,19,41
Breslow’s tumor thickness is described in vari-
ous studies as the most important prognostic factor
for CM.2,42
According to the most recent version of the
American Joint Committee on Cancer (AJCC), MMs
are classified, based on Breslow’s depth, as thin (≤ 1
mm), intermediate (1,01-4 mm) and thick (>4 mm).42 In
recent years some papers, from many areas of the
world, have mentioned an increase in the incidence of
cases of thin CM, as well as the stabilization of the
incidence of thick ones.2,18,20,43 Regarding the Brazilian
literature, some authors have also found a high pro-
portion of cases of thin CM, which is, therefore, in
concordance with the findings in the international lit-
erature.14,15,22,44
In the sampling presented here, 72% of the
cases of CM were restricted to the epidermis (in situ)
or had a tumor thickness of ≤ 1 mm. One possible
explanation for the predominance of CM in initial
stages results from the diagnosis being made, in the
majority of cases, by dermatologists, which con-
tributed to the early identification of the tumor.45
The Clark level, or the tumor invasion level, was
initially considered an independent prognostic factor.
In the 2002 version of the AJCC’s staging, this index
was computed in order to evaluate the prognosis of
lesions with a Breslow’s depth of < 1 mm.42 Now, the
Clark level is considered in the staging of thin CMs
only when information on ulceration and the mitotic
index is not available.42 In the present study, 55.1% of
the patients presented Clark levels I and II, as found in
the international literature, which reveals the predom-
inance of lesions with lower invasion levels.20,46
Changes in color and size of a previous lesion
and the appearance of a new lesion are the earliest
characteristics that are noted by patients and that con-
tribute to the diagnosis. Of these, growth has been
highlighted as the most frequent clinical sign, followed
by alterations in color.19,24,47 While in some studies
growth has been associated with greater tumor thick-
ness, in another this association was not detected.19,24,47
Alterations in color have been related to thinner
CM and bleeding from thicker lesions.19,24,47 There is
disagreement between authors regarding alterations
in sensitivity, especially itching. For some, this is cor-
related with thin tumors while others associate it with
thicker ones.10,19,24,47 In this study, 70.6% of the patients
reported symptoms and/or signs in the lesion. The
most common complaint was growth of the lesion,
followed by darkening, itching and, less frequently,
bleeding. This bleeding was associated with cases of
thicker CM and was similar to the findings of the
studies mentioned.19,24,47
Alterations in color, sensitivity and growth
were more frequent in cases of thinner CM, though
with no statistical significance.
Metastases denote a poor prognosis, with sur-
vival times estimated in months. As a rule, the greater
the thickness of the tumor, the greater the chances of
metastasis.46 Cases of CM diagnosed with a Breslow’s
thickness < 1.5 mm show 10-year survival rates above
90%.48 The CM disseminates via lymphatic and/or
hematogenic routes. The former occurs very early in
the evolution of CM. Distant metastases may be either
non-visceral (skin, subcutaneous tissue and non-
regional lymph node), or visceral, most frequently
affecting the lungs (18- 36%), followed by the liver (14-
20%), brain (12-20%), bones (11-17%) and gastroin-
testinal tract (1-7%).10
In the sample assessed, metastases were found
in 19 (13.4%) patients, with the lymph nodes being the
most common (40%). In 80% of the patients suffering
from a metastasized disease, the tumor thickness was
> 1.5 mm, which is similar to the findings from the lit-
erature referred to above.
In addition to tumor thickness, other factors asso-
ciated with survival rates are: sex, age, primary body
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location, histological type, skin color and staging.10
The men presented a higher proportion of cases
of thick CM than the women, resulting in worse sur-
vival rates.3,15,18,24 Patients over the age of 60 also had
poor prognoses with an elevated proportion of cases
of thick CM.3,18,49 Balch et al recorded that, even when
controlling confusing factors such as gender and
tumor thickness, age was an independent prognostic
factor in CM.46 This may be attributed to a decline in
the immunological response which occurs with
age.46,49
Regarding body location, the majority of the
authors consider the trunk to be the location with the
poorest prognosis.3,15,18,25,47 In relation to the histological
type, some investigations have observed worse sur-
vival rates with NM15,18 while others have recorded
that ALM was associated with a poorer prognosis.47
As for skin color, Chang et al recorded worse
survival rates for non-white individuals both in the
initial and later stages, though this association did not
have an impact on the multivariate analysis.18
In this sample a greater chance of death was
found among men, those under the age of 20, non-
whites, those with the ALM histological type, those
with a Breslow’s depth > 2 mm and those with a his-
tory of growth and bleeding. However, following the
multivariate analysis, only the patients under the age
of 20 and with a history of bleeding remained at high
risk.
Children and adolescents suffer from CM less
frequently than adults, which may delay diagnosis,
thereby worsening survival rates.10,41,50 The two cases
diagnosed in children occurred in patients bearing
GCMN, which is known to carry a poor prognosis,
since two thirds of cases of CM in people with GCMN
are of a non-epidermic origin, which leads to a late
diagnosis and, consequently, reduced survival rates.41
Bleeding is most common in cases of thick CM
according to the literature and to the results found in
this study, which denotes a poor prognosis.19,24,47
CONCLUSIONS
In conclusion, in this sample, cases of CM were
more common in women, with a mean age of 55 years
at diagnosis. Whites represent the majority of patients,
but the proportion of non-whites is bigger than other
Brazilian states, justifying the higher frequency of
ALM than cited in other studies. The most frequent
histological type was LM/LMM, that could be
because of regional factors and matches with predom-
inant location. Comparing sex and body site, CM was
more common in trunk of men and limbs of women.
In agree with national and international tendencies,
the majority of CM was in situ or thin. The number of
deaths was small, with more chances of dying in those
under 20 years and with a history of bleeding, after a
multivariate analysis. In that way, more attention
should be taken to children and teenagers, mostly
those with predisposing factors such GCMN, PX and
atypical nevus, besides CM in these population being
rare, the diagnosis of CM with less than 1 mm of
growth, is still the best chance of cure for the most
lethal type of skin cancer.
This sample analyzed is small and came from a
single institution, meaning that these findings cannot
be generalized for the entire population of the state.
This data may not reflect the reality of CM among the
population of this state. Further studies are necessary
in order to validate the results obtained. However, this
study represents the largest sampling of patients with
melanoma in this state, with data collected over the
longest period of time. ❑
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